+91-8668442535

Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitors, Kallikrien Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Product Drugs (Phase Iii Drug, Phase Ii Drug (Qualitative Information) ) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied by swelling of the legs, intestinal tract, arms, face, and airway tract. There are three types of hereditary angioedema, types I, II, and III, which are distinguished by the underlying causes and the levels of a blood protein called C1 inhibitors. The phenotypic expression of hereditary angioedema varies widely, even among family members; the frequency and severity of attacks are unpredictable, giving the impression that similar symptoms arise in all types. Type III was initially thought to be prevalent only in women, but incidences have occurred in males in the same affected families.

For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs, and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze, and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonists (Firazyr), others. DX-2930, a phase III drug, and BCX-7353, a phase II drug, are currently in the pipeline for this market. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The geographic segmentation of the global hereditary angioedema market is performed for the regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

Based on drug class, the global hereditary angioedema market is categorized into:

  • C1 Esterase Inhibitors
  • Berinert
  • Haegarda
  • Cinryze
  • Ruconest
  • Kallikrein Inhibitor
  • Kalbitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Firazyr
  • Others

The hereditary angioedema market is driven by factors such as increasing expenditure in pharmaceutical and biotechnology R&D focusing on rare genetic diseases, rising public awareness, and alliances between pharmaceutical giants and research institutes. In addition, the increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration of hereditary angioedema drugs. In 2016, the C1 esterase inhibitors segment held the largest market share, chiefly due to factors such as the recent FDA approval of Berinert and Haegarda.

Technological advancement in the drug delivery system, e.g., Haegarda, is the only medication available as a subcutaneous treatment option for hereditary angioedema. Kallikrein inhibitors will be the fastest-growing segment throughout the forecast period of 2017–2025. Factors contributing to the growth of this segment include increasing incidences in patients with angioedema and anaphylactic shock and a promising product pipeline consisting of selective kallikrein inhibitors and plasma kallikrein inhibitors, which result in immediate relief due to their faster onset of action. The major players in the hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

For the purpose of this study, the global hereditary angioedema market is categorized into the following regional and country-specific markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

In the base year 2016, North America was observed to be the largest market for hereditary angioedema. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered from hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as the rising prevalence of hereditary angioedema, the presence of pharmaceutical giants such as BioCryst Pharmaceuticals, Inc. and CSL Behring, and the existence of developed research and healthcare institutions.

The market growth in Europe is mainly attributed to the rising prevalence of rare genetic diseases, the increasing demand for novel drugs for the treatment of hereditary angioedema, and an affordable reimbursement scenario for the treatment of rare genetic diseases. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are increasing disposable income and a supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure and expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of the hereditary angioedema market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Questions:

The market for Hereditary Angioedema Market is expected to reach US$ 3,689.4 Mn By 2025.

The Hereditary Angioedema Market is expected to see significant CAGR growth over the coming years, at 8.19%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58675
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support